Repository logo
 

Remyelination in humans due to a retinoid‐X receptor agonist is age‐dependent

Published version
Peer-reviewed

Change log

Authors

McMurran, Christopher E.  ORCID logo  https://orcid.org/0000-0002-8710-0930
Mukherjee, Trisha 
Michell, Andrew W. 
Chard, Declan T. 

Abstract

Abstract: Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid‐X receptor agonist, shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age); and increased the magnetization transfer ratio of deep gray matter lesions in those under 43 years only. Addressing this age‐related decline in human remyelination capacity will be an important step in the development of remyelinating therapies that work across the lifespan.

Description

Funder: Cambridge NIHR Biomedical Centre


Funder: Cambridge NIHR Clinical Research Facility

Keywords

Brief Communication, Brief Communications

Journal Title

Annals of Clinical and Translational Neurology

Conference Name

Journal ISSN

2328-9503

Volume Title

Publisher

Sponsorship
UK Multiple Sclerosis Society (RRZD/004 Task 3 Sub‐contracting (RG59911))